Methinks the resource boom is over and there is starting to be a...

Methinks the resource boom is over and there is starting to be a lot of positive news coming from the Biotech sector, with money moving in.
A good indication is the increase from overseas managed funds placing capital into Australian Biotechs, and some good Phase 2 results from compaines such as Progen will help the momentum.
In regards to HTW, evidence from cardiac surgeons who have seen the HVAD say it is the best 3G LVAD around and will be preferred be all surgeons. It is small, 1/3rd size of ventrassist, only 3G pump implantable routinely above the diaphram (which means no adominal surgery) which leads to lower infection risks. Pump has low haemolysis, which is fantastic along with no clotting!!! Also having companies such as VCR and Thoratec doing the hard yards and establishing the LVAD markets only helps HTW's pathway to acceptance.
Having six patients alive and doing extremely well with the HVAD's is conclusive evidence that the HVAD works eceptionally well, and now that they are on their way to CE mark, I think they will be ripe for a takeover from one of the large American medical companies such as J&J, Medtronics, Thoratec, Etc.